For decades, catching cancer early has meant a patchwork of separate tests, each aimed at a single organ: a mammogram for breast tissue, a colonoscopy for the bowel, a smear for the cervix. Most cancers have no screening test at all, which is why so many are still found only after symptoms appear and the disease has spread. A blood test called Galleri was built to change that arithmetic, and at the end of May 2026 the largest trial ever run on it finally reported what it can and cannot do.
The results, presented on 30 May at the American Society of Clinical Oncology meeting, came from the NHS-Galleri trial in England, which followed more than 142,000 volunteers aged 50 to 77. They are the clearest look yet at whether one tube of blood can flag dozens of cancers at once, and they land just as the test starts to reach Canadians.
How One Blood Test Looks for Fifty Cancers
Galleri, made by the California company GRAIL, does not hunt for tumours directly. It reads fragments of DNA that dying cells shed into the bloodstream. Healthy cells and cancer cells both leak this material, but cancer leaves a distinctive chemical signature in the way its DNA is tagged with methyl groups, a kind of molecular punctuation that switches genes on and off. The test scans for those patterns across more than fifty cancer types and, when it finds a suspicious signal, makes a second prediction: which organ the signal most likely came from.
That second step matters more than it sounds. A positive result that simply said “cancer somewhere” would send doctors on an expensive, anxious hunt through the whole body. By pointing to a likely origin, the test narrows the follow-up to a scan or two. The same logic of targeting at the molecular level runs through much of modern oncology, from nanoscale machines built to deliver drugs straight to tumour cells to the protein-modelling tools reshaping how new cancer drugs are designed.
What the NHS-Galleri Trial Actually Found
The numbers are striking in places and sobering in others. When the test returned a positive result, cancer was confirmed about 52 percent of the time, rising to 58 percent in the first round of screening. For context, only around 6 percent of people sent for urgent cancer investigation on the NHS turn out to have the disease, so a coin-flip’s odds from a single blood draw is a high bar to clear.
The test was also very good at not crying wolf. Its specificity reached 99.55 percent, meaning fewer than one in 200 healthy people got a false alarm. And when it did flag a cancer, it named the right organ of origin 92.5 percent of the time, which is what makes the result something a doctor can act on quickly.
Sensitivity, the share of real cancers the test actually caught, is where expectations need tempering. Across the twelve cancer types the trial singled out in advance, Galleri picked up about 55 percent of cases. Across all cancers, including early and slow-shedding tumours, that figure fell to roughly 31 percent. In plain terms, the test still misses more cancers than it finds, especially the smallest ones that shed little DNA.
The Signal That Got Everyone’s Attention
The headline finding was not an accuracy score but a shift in timing. In the second and third rounds of screening, the trial recorded more than a 20 percent drop in cancers diagnosed at stage IV, the most advanced and least treatable stage. Pulling diagnoses earlier is the whole point of screening, because a cancer caught at stage I or II is usually cheaper to treat and far more survivable.
Researchers were careful, though, not to declare victory. A drop in late-stage diagnoses is a promising sign, not proof that the test saves lives. That harder question, whether people screened with Galleri actually live longer, needs years more follow-up. Cancer screening has a long history of tests that found more disease without changing how many people died from it, and the trial’s leaders said as much when they presented the data.
What the Test Cannot Do
Galleri is not a replacement for the screening that already exists. It is poor at catching some cancers that mammograms and colonoscopies catch well, which is why doctors stress that a clear Galleri result is no reason to skip a scheduled colon screening or a routine mammogram. A negative test does not mean a person is cancer-free; it means no strong signal turned up that day.
There are subtler risks too. Any test run on healthy people will occasionally find cancers that would never have caused harm, leading to treatment that does more damage than the disease would have. And a false positive, while rare, can mean months of scans and biopsies before the all-clear. Understanding why some tumours turn aggressive while others sit quietly is still an open problem, one that work on the genetics of cancer across species is slowly helping to answer.
Coming to Canada
Galleri is already trickling into Canada through an unusual door: life insurance. Manulife became the first Canadian insurer to offer the test to eligible customers, partnering with the Toronto health company Medcan, which serves as GRAIL’s official Canadian provider. Eligible clients can have the blood drawn at Medcan’s clinics in Toronto and Oakville.
For now, that makes early access in Canada a matter of who holds your insurance rather than what your family doctor recommends. The test is not part of any public screening programme here, and it is not cheap when paid for privately, with sticker prices that have run close to a thousand dollars per test elsewhere. Whether provincial health systems ever fold a test like this into routine care will depend on cost, on those longer-term survival data, and on regulators.
The Regulatory Road Ahead
GRAIL filed the final piece of its premarket approval application with the United States Food and Drug Administration in late January 2026. The agency has no equivalent test approved yet, and a decision could stretch well beyond the nominal review window as reviewers ask for more data. Health Canada has not cleared Galleri for routine clinical use either, which is part of why it currently reaches Canadians through private clinics rather than the public system.
A green light from the FDA would be a turning point, both for Galleri and for the handful of rival multi-cancer tests moving through trials behind it. It would also force a broader conversation about who pays, who qualifies, and how to counsel people through a result that is meaningful but far from certain.
Not the Only Test in the Race
Galleri has the spotlight because it has the biggest trial behind it, but it is far from alone. Several companies are developing their own multi-cancer detection tests, some reading the same cell-free DNA, others looking at proteins or fragments of RNA. A few are paired with artificial intelligence trained to spot patterns a human eye would miss. The competition is good news for patients, because rival tests push each other toward better sensitivity and lower prices. The likeliest future is a panel of complementary tools rather than one blood draw that does everything, much as today’s screening already relies on several methods aimed at different organs.
Should You Consider It?
For anyone weighing the test, the honest answer is that it is a supplement, not a safety net. It can surface cancers that have no other screening test, which is genuinely new and potentially life-changing for a minority of users. It can also miss real cancers, raise false alarms, and lull people into skipping the screening that already works. Those trade-offs are personal, and they are best talked through with a doctor who knows your history rather than decided from a marketing page.
What the NHS-Galleri results make clear is that the technology has crossed from promise into something measurable. It is not the universal cancer test the early headlines imagined, but it is real, it is improving, and for the first time there is hard evidence about exactly how well it works.
This article is for general information and is not medical advice. Anyone with questions about cancer screening should speak with a qualified healthcare professional.
